SR One, a venture capital firm focused on the biotech space, is looking to raised up to $400m for its new fund.
The firm has yet to register any capital for SR One Capital Fund I, according to the latest US Securities and Exchange Commission filing.
It is unclear whether the $400m figure on the document is just a target or will also be a hardcap for the fundraise.